The latest price of acalatinib/acalatinib medical insurance in 2024

AcalabrutinibAcalabrutinib is a drug used to treat various types of non-Hodgkin lymphoma, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). It can be used both for relapse and for first time treatment.

Acotinib is a second-generation Bruton's tyrosine kinase inhibitor that blocks an enzyme calledBruton's tyrosine kinase, which helps B cells survive and grow. By blocking this enzyme, acotinib is expected to slow the accumulation of cancerous B cells in CLL, thereby slowing the progression of the cancer. Common side effects include headache, feeling tired, a decrease in red blood cells, a decrease in platelets, and a decrease in white blood cells. Acotinib was approved for medical use in the United States in 2017 and in the European Union in November 2020.

Fortunately, the original drug acotinib has been officially launched in China and has been included in the medical insurance system, making this drug accessible to more patients. The common drug specifications are 100mg, 8 pills and 7 tablets, but the price per box is as high as more than 40,000 yuan. Due to different reimbursement ratios in different regions, the price after reimbursement by medical insurance may be slightly different for patients. For specific information about medical insurance, please consult the local medical insurance bureau or hospital.

At the same time, the price of the same original drug overseas has soared to more than 10,000 US dollars. The price is indeed staggering. At present, generic drugs of acotinib are on the market, and their medicinal ingredients are almost the same as those of the original drugs at home and abroad. For example, a pharmaceutical company in Laos has launched a 100mg*60-tablet medicine. Each box is priced at just over 3,000 yuan. Of course, this price may be adjusted due to exchange rate changes.